Emergent BioSolutions Inc.: Form 10-Q for the period ended Jun 30, 2014
Filed with the SEC on Aug 8, 2014 and accepted by EDGAR at Aug 7, 2014, 22:48 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-04-01 to 2014-06-30 | $110.3m | us-gaap:Revenues |
| Revenue | 6 months2014-01-01 to 2014-06-30 | $164.2m | us-gaap:Revenues |
| Cost of revenue | 3 months2014-04-01 to 2014-06-30 | $34.5m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2014-01-01 to 2014-06-30 | $53.5m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2014-04-01 to 2014-06-30 | $37.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2014-01-01 to 2014-06-30 | $67.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2014-04-01 to 2014-06-30 | $30.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2014-01-01 to 2014-06-30 | $60.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2014-04-01 to 2014-06-30 | $7.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2014-01-01 to 2014-06-30 | −$17.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2014-04-01 to 2014-06-30 | $1.7m | us-gaap:InterestExpense |
| Interest expense | 6 months2014-01-01 to 2014-06-30 | $5.3m | us-gaap:InterestExpense |
| Income tax | 3 months2014-04-01 to 2014-06-30 | $2.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2014-01-01 to 2014-06-30 | −$5.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-04-01 to 2014-06-30 | $5.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2014-01-01 to 2014-06-30 | −$15.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-04-01 to 2014-06-30 | $0.13 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2014-01-01 to 2014-06-30 | −$0.41 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-04-01 to 2014-06-30 | $0.13 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2014-01-01 to 2014-06-30 | −$0.41 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2014-04-01 to 2014-06-30 | 38,333,425 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2014-01-01 to 2014-06-30 | 37,137,015 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2014-01-01 to 2014-06-30 | −$18.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2014-01-01 to 2014-06-30 | $9.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2014-06-30 | $168.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-06-30 | $345.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-06-30 | $837.2m | us-gaap:Assets |
| Current liabilities | At period end2014-06-30 | $76.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-06-30 | $349.5m | us-gaap:Liabilities |
| Long-term debt | At period end2014-06-30 | $251.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2014-06-30 | $487.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001367644-14-000037. Last ingested by Listed: Nov 4, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.